The University of Chicago Header Logo

Connection

Rudolph Navari to Induction Chemotherapy

This is a "connection" page, showing publications Rudolph Navari has written about Induction Chemotherapy.
Connection Strength

0.384
  1. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol. 2019 Jan; 15(3):241-255.
    View in: PubMed
    Score: 0.154
  2. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016 May; 24(5):2381-2392.
    View in: PubMed
    Score: 0.127
  3. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 07 01; 29(7):1535-1540.
    View in: PubMed
    Score: 0.038
  4. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017 01; 25(1):303-308.
    View in: PubMed
    Score: 0.034
  5. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016 Feb; 24(2):1001-1008.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.